The Europe CRISPR Market was valued at $784.2 Million in 2025 and projected to reach to $1339.9 Million by 2030, representing a compound annual growth rate of 11.2%. Europe's CRISPR market is poised for sustained expansion through 2030, driven by increasing clinical trial approvals, growing therapeutic applications, and rising healthcare expenditure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's CRISPR market is valued at $784.2 million in 2025, with a projected expansion to $1,339.9 million by 2030, representing an 11.2% CAGR. This robust growth trajectory positions Europe as a critical player in the global gene-editing landscape.
Europe benefits from well-established regulatory frameworks that facilitate innovation while ensuring safety standards. The European Medicines Agency (EMA) provides clear pathways for CRISPR-based therapeutics, attracting significant investment and clinical trial activity across the region.
Germany, the United Kingdom, and Switzerland serve as epicenters of CRISPR innovation in Europe. These countries host leading biotech firms, research institutions, and venture capital funding, driving technological advancement and commercialization of gene-editing therapies.
Substantial public and private R&D investments across European nations fuel CRISPR development. Government funding initiatives, EU research programs, and corporate partnerships accelerate the translation of CRISPR technology from laboratory to clinical applications.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
6 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 26.1 | 27.4 | 30.1 | 33.3 | 36.8 | 40.7 | 45 | 49.8 | 10.6 |
| OTHER END USERS | 36.1 | 37.9 | 41.7 | 46 | 50.7 | 56 | 61.9 | 68.4 | 10.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 37.3 | 39.2 | 43.3 | 48 | 53.2 | 59 | 65.5 | 72.7 | 11 |
| TOTAL | 99.5 | 104.4 | 115.1 | 127.3 | 140.7 | 155.6 | 172.4 | 190.9 | 10.7 |
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 55.6 | 60.3 | 67.2 | 75.3 | 84.2 | 94.2 | 105.5 | 118.3 | 12 |
| OTHER END USERS | 60.7 | 65.6 | 72.4 | 80.3 | 88.9 | 98.4 | 109.1 | 121 | 10.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 74 | 80.3 | 89.7 | 100.7 | 112.9 | 126.6 | 142.2 | 159.8 | 12.2 |
| TOTAL | 190.3 | 206.2 | 229.4 | 256.3 | 285.9 | 319.2 | 356.9 | 399.1 | 11.7 |
| Country | 2025 size (native) |
|---|---|
| Germany | USD 376.9 Million |
| UK | USD 284.7 Million |
| France | USD 152.1 Million |
| Italy | USD 84.8 Million |
| Spain | USD 54 Million |
| Rest Of Europe | USD 190.9 Million |
Europe's CRISPR market is projected to reach $1,339.9 million by 2030, growing from $784.2 million in 2025 at an 11.2% CAGR.
The United Kingdom, Germany, and Switzerland are leading CRISPR innovation in Europe, hosting major biotech firms, research institutions, and clinical trial centers.
The European Medicines Agency (EMA) is establishing clearer pathways for CRISPR therapy approval, and expanding reimbursement frameworks are supporting faster commercialization across European healthcare systems.
Oncology, rare genetic disorders, and immunotherapy are the primary therapeutic areas driving CRISPR adoption and market expansion in Europe.
Europe represents a significant portion of the global CRISPR market, with strong R&D capabilities, regulatory support, and clinical infrastructure positioning it as a key regional growth driver alongside North America and Asia-Pacific.
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all CRISPR Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report